Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy

PHASE3CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

June 26, 2019

Study Completion Date

June 26, 2019

Conditions
MEMBRANOUS NEPHROPATHY
Interventions
DRUG

TACROLIMUS

Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.

DRUG

RITUXIMAB

A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction

DRUG

METHYLPREDNISOLONE

Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.

DRUG

CYCLOPHOSPHAMIDE

Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.

Trial Locations (1)

Unknown

Hospital 12 de Octubre, Madrid

All Listed Sponsors
collaborator

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

OTHER

collaborator

Hospital Universitario Fundación Alcorcón

OTHER

collaborator

Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre

UNKNOWN

collaborator

Biobanco REDinREN

UNKNOWN

collaborator

ERA-EDTA

UNKNOWN

collaborator

REDinREN

UNKNOWN

collaborator

Spanish Society of Nephrology

OTHER

collaborator

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

OTHER

collaborator

University Hospital, Aachen

OTHER

lead

Hospital Universitario 12 de Octubre

OTHER

NCT01955187 - Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy | Biotech Hunter | Biotech Hunter